- Meeting abstract
- Open Access
CSII treatment as an option in high-risk pregnant patients with type 1 diabetes
© Breder et al. 2015
- Published: 11 November 2015
- Glycemic Control
- Pregnant Patient
- Diabetes Duration
- Diabetic Ketoacidosis
- Continuous Subcutaneous Insulin Infusion
Studies highlight that continuous subcutaneous insulin infusion (CSII) during pregnancy leads to better glycemic control and lower glycated hemoglobin (HbA1c) without an increase in hypoglycemic episodes or diabetic ketoacidosis. Poor glycemic control can lead to birth defects, miscarriages, growth abnormalities and stillbirth. However, how to obtain better gestational outcomes is still debatable.
Evaluate glycemic control in pregnant women with type 1 diabetes (T1D) in use of CSII, assessing the improvement of glycemic control and gestational outcomes.
This is a descriptive, single observer study carried out in a specialized endocrinology clinic. Eight pregnant patients with T1D in use of CSII and nine newborns were evaluated. Maternal variables analyzed were: age, diabetes duration, time of CSII Background during pregnancy, HBA1C before and during pregnancy; and newborn variables: intensive unit care (ICU) admission, neonatal hypoglycemia, prematurity, low birth weight and large for gestational age (LGA).
Mean age at pregnancy was 29.3 (±4.1) yrs. Mean diabetes duration before pregnancy was 11.9 (±5.6) yrs. Five of eight (62.5%) had an absolute contraindication to pregnancy. Three (37.5%) became pregnant already in use of CSII; one (12.5%) started CSII in the first trimester and four (50%) in the second trimester. All but one was subjected to cesarean delivery. None had diabetic ketoacidosis. There was a significant HbA1c decrease in the third trimester compared to pre-pregnancy values (6.8% vs 9.4%, p=0.028) and from the second to first trimester (7.1% vs 8.1%, p=0.043). There was one twin pregnancy. There were no stillbirths, miscarriages or congenital anomalies. Five of nine babies (55.6%) were premature, four (44.4%) were required ICU admission, five (55.6%) had neonatal hypoglycemia and three (33.3%) were LGA. Prematurity was more common in older mothers (p=0.029).
As expected, CSII in pregnancy leads to a reduction in HBA1c without increasing the frequency of diabetic ketoacidosis, even in high-risk patients or those with previous poor compliance. The relatively good Results achieved in this group of patients with previous adverse conditions for pregnancy could related to the attainment of better glycemic control with CSII. Therefore, we believe that CSII treatment could be an option for patients that start pregnancy with a poor prognosis.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.